home All News open_in_new Full Article

China’s new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?

Mainland China’s 17 million Alzheimer’s patients can, for the first time, pay less out of pocket for a costly drug touted as “historic” and “the beginning of the end” for the memory-robbing disease after Beijing launched a commercial insurance innovative drug list in an effort to make medicines more accessible and affordable. Leqembi, developed by Japan’s Eisai and costing a mainland Chinese patient about US$28,400 a year, could see its price cut by half after it was added to the inaugural...


today 2 d. ago attach_file Events

attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Economics
attach_file Events
attach_file Politics
attach_file Events
attach_file Economics
attach_file Events
attach_file Society
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Events


ID: 3516317502
Add Watch Country

arrow_drop_down